

AGV Discovery Announces First Patient Dosed in Phase 1/2

MONTFERRIER-SUR-LEZ, FRANCE, April 30st, 2024, AGV Discovery today announced that the first participant has been dosed in the Phase 1/2 clinical trial evaluating IPN01194 in patients with MAPK α advanced solid tumors.

Cédric Boriès, President for AGV Discovery commented, “We are very pleased to announce the first dosing in humans of our drug candidate IPN01194 in collaboration with our partner Ipsen. This represents a very important milestone for us and for the patients we hope to serve. This success is the result and the demonstration of the efficiency of our drug design platform, based on innovative conception approaches”.

The Phase 1/2 trial will evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and anti-tumors activity of ERK1/2 inhibitor IPN01194 as single agent in adult participants with advanced solid tumors.

About AGV Discovery

AGV Discovery is a product-driven pharmaceutical company specialized in the discovery and early stage development of innovative medicines in oncology. Medical research within the company is focused on identifying new druggable therapeutic targets, considered today as a priority for the treatment of aggressive cancers. Thanks to powerful tools such as crystallography and computerized computational drug design, the company develops series of active molecules on these new targets of interest using the so-called Fragment Based Drug Design techniques. AGV Discovery leads its drug discovery projects up to the regulatory phases by combining its knowledge in drug design, medicinal chemistry, translational research and early ADME Tox then in collaboration with major pharmaceutical companies for further development.

AGV Discovery is supported by Liberi Group.

For further information:

Contacts

AGV Discovery:

Cédric Boriès

President

Investors@agv-discovery.com

Liberi Group:

Frans Trouwen

FransTrouwen@LiberiGroup.com

AGV Discovery:

Cédric Boriès

President

Contact@agv-discovery.com